Gyros Protein Technologies introduces Gyrolab Generic Anti-AAV Kit to support gene therapy development Post author: Post published:June 17, 2024 Post category:uncategorized Ready-to-use kit enables detection of binding antibodies against AAV vectors without the need for serotype-specific assays. You Might Also Like Implanted vagus nerve stimulation device offers lasting relief for severe depression January 13, 2026 LabVantage Solutions awarded $22.3 million U.S. customs and border protection contract to deliver next-generation forensic LIMS November 12, 2025 Streamlining Ethics Approval for Research Using Routinely Collected Health Data: A Case Study of Hong Kong December 3, 2023
Implanted vagus nerve stimulation device offers lasting relief for severe depression January 13, 2026
LabVantage Solutions awarded $22.3 million U.S. customs and border protection contract to deliver next-generation forensic LIMS November 12, 2025
Streamlining Ethics Approval for Research Using Routinely Collected Health Data: A Case Study of Hong Kong December 3, 2023